Dangers of growth hormone therapy in critically ill patients

References

• Riedel M, Brabant G, Rieger K, von zur Muehlen. Growth hormone therapy in adults: rationales, results, and perspectives. Exp Clin Endocrinol 1994; 102: 273–83
   PubMedGoogle Scholar
• Wilmore D W. Catabolic illness: strategies for enhancing recovery. N Engl J Med 1991; 325: 695–702
   PubMed Web of Science ®Google Scholar
• Rennie M J. Muscle protein turnover and the wasting due to injury and disease. Br Med Bull 1985; 41: 257–64
   PubMed Web of Science ®Google Scholar
• Arnold J, Campbell I T, Samuels T A, Devlin J C, Green C J, Hipkin L J, et al. Increased whole body protein breakdown predominates over increased whole body protein synthesis in multiple organ failure. Clin Sci 1993; 84: 655–61
   Web of Science ®Google Scholar
• Ross R, Miell J, Freeman E, Jones J, Matthews D, Preece M, et al. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-1. Clin Endocrinol 1991; 35: 47–54
   PubMed Web of Science ®Google Scholar
• Van den Berghe G, De Zegher F, Veldhuis J D, Wouters P, Awouters M, Verbruggen W, et al. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab 1997; 82: 590–9
   PubMed Web of Science ®Google Scholar
• Timmins A C, Cotterill A M, Cwyfan Hughes S C, Holly J MP, Ross R MJ, Blum W, et al. Critical illness is associated with low levels of insulin-like growth factor-1 (IGF-I) and IGF-11, alterations in IGF binding proteins (IGFBP) and induction of an IGFBP-3 protease. Crit Care Med 1996; 24: 1460–6
   PubMed Web of Science ®Google Scholar
• Manson J M, Smith R J, Wilmore D W. Growth hormone stimulates protein synthesis during hypocaloric parenteral nutrition. Role of hormonal-substrate environment. Ann Surg 1988; 208: 136–42
   PubMed Web of Science ®Google Scholar
• Ziegler T R, Young L S, Manson J M, Wilmore D W. Metabolic effects of recombinant human growth hormone in patients receiving parenteral nutrition. Ann Surg 1988; 208: 6–16
   PubMed Web of Science ®Google Scholar
• Ponting G A, Halliday D, Teale J D, Sim A JW. Postoperative positive nitrogen balance with intravenous hyponutrition and growth hormone. Lancet 1988; i: 438–40
   Google Scholar
• Ziegler T R, Rombeau J L, Young L S, Fong Y, Marano M, Lowry S F, et al. Recombinant human growth hormone enhances the metabolic efficacy of parenteral nutrition: a double-blind, randomised controlled study. J Clin Endocrinol Metab 1992; 74: 865–73
   PubMed Web of Science ®Google Scholar
• Knox J, Demling R, Wilmore D, Sarraf P, Santos A. Increased survival after major thermal injury: the effect of growth hormone therapy in adults. J Trauma 1995; 39: 526–30
   PubMedGoogle Scholar
• Herndon D N, Barrow R E, Kunkel K R, Broemeling L, Rutan R L. Effects of recombinant human growth hormone on donor site healing in severely burned children. Ann Surg 1990; 212: 424–9
   PubMed Web of Science ®Google Scholar
• Gore D C, Honeycutt D, Jahoor F, Wolfe R R, Herndon D N. Effect of exogenous growth hormone on whole body and isolated limb protein kinetics in burned patients. Arch Surg 1991; 126: 3843
   Google Scholar
• Hammarqvist F, Stromberg C, von der Decken A, Vinnars E, Wernerman J. Biosynthetic human growth hormone preserves both muscle protein synthesis and prevents the decrease in muscle-free glutamine and improves whole body-nitrogen economy after operation. Ann Surg 1992; 216: 184–91
   PubMed Web of Science ®Google Scholar
• Jiang Z -M, He G -Z, Zhang S -Y, Want X -R, Yang N -F, Shu Y, et al. Low-dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation. Ann Surg 1989; 210: 513–25
   PubMed Web of Science ®Google Scholar
• Voerman B J, Strack van Schijndel R J, deBoer H, Groeneveld A B, Nauta J P, van der Veen E A, et al. Effects of recombinant human growth hormone in patients with severe sepsis. Ann Surg 1992; 216: 648–55
   PubMed Web of Science ®Google Scholar
• Voerman B J, Strack van Schijndel R JM, Groenveld A B, De Boer H, Nauta J P, Thijs L G. Effects of human growth hormone in critically ill nonseptic patients: results from a prospective randomised, placebo-controlled trial. Crit Care Med 1995; 23: 665–73
   PubMed Web of Science ®Google Scholar
• Pape G S, Friedman M, Underwood L E, Clemmons D R. The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest 1991; 99: 1495–500
   PubMed Web of Science ®Google Scholar
• Suchner U, Rothkopf M M, Stanislans G, Elwyn D H, Kvetan V, Askanazi J. Growth hormone and pulmonary disease. Metabolic effects in patients receiving parenteral nutrition. Arch Intern Med 1990; 150: 1225–30
   PubMedGoogle Scholar
• Knox J B, Wilmore D W, Demling R H, Sarraf P, Santos A A. Use of growth hormone for postoperative respiratory failure. Am J Surg 1996; 171: 576–80
   PubMed Web of Science ®Google Scholar
• Pichard C, Kyle U, Chevrolet J -C, Jolliet P, Slosman D, Mensi N, et al. Lack of effects of recombinant growth hormone on muscle function in patients requiring prolonged mechanical ventilation: a prospective, randomised, controlled study. Crit Care Med 1996; 24: 403–12
   PubMed Web of Science ®Google Scholar
• Takala J, Ruokonen E, Webster N R, Nielsen M S, Zandstra D F, Vundelinckx G, et al. Increased mortality associated with growth hormone treatment in critically ill patients. N. Engl J Med 1999; 341: 785–92
   PubMed Web of Science ®Google Scholar
• Knaus W A, Draper E A, Wagner D P, Zimmerman J E. APACHE 11: a severity of disease classification system. Crit Cure Med 1985; 13: 818–29
   PubMed Web of Science ®Google Scholar
• Warwick-Davies J, Lowrie D B, Cole P J. Growth hormone is a human macrophage activating factor. Priming of human monocytes for enhanced release of H. O. J Immunol 1995; 154: 1909–18
   PubMed Web of Science ®Google Scholar
• Edwards C K, Ghiasuddin S M, Schepper J M, Yunger L M, Kelley K W. A newly defined property of somatotropin: priming of macrophages for production of superoxide anion. Science 1988; 239: 769–71
   PubMed Web of Science ®Google Scholar
• Kappel M, Hansen M B, Diamant M, Pedersen B K. In vitro effects of human growth hormone on the proliferative responses and cytokine production of blood mononuclear cells. How Metab Res 1994; 26: 6124
   Web of Science ®Google Scholar
• Elsasser T H, Fayer R, Rumsey T S, Hartnell G F. Recombinant bovine somatotropin blunts plasma tumour necrosis factor-alpha, cortisol and thromboxane-B2 responses to endotoxin in vivo. Endocrinology 1994; 134: 1080–2
   Web of Science ®Google Scholar
• Inoue T, Saito H, Fukushima R, Inaba T, Lin M T, Fukatsu K, et al. Growth hormone and insulin-like growth factor-I enhance host defense in a murine sepsis model. Arch Surg 1995; 130: 1115–22
   PubMedGoogle Scholar
• Liao W, Rudling M, Angelin B. Growth hormone potentiates the in vivo biological activities of endotoxin in the rat. Eur J Clin Invest 1996; 26: 254–8
   PubMed Web of Science ®Google Scholar
• Liao W, Rudling M, Angelin B. Contrasting effects of growth hormone and insulin-like growth factor-I on the biological activities of endotoxin in the rat. Endocrinology 1997; 138: 289–95
   PubMed Web of Science ®Google Scholar
• Knox J B, Demling R H, Wilmore D W, Sarraf P, Santos A A. Hypercalcemia associated with the use of human growth hormone in an adult surgical intensive care unit. Arch Surg 1995; 130: 442–5
   PubMedGoogle Scholar
• Van Den Berghe G, De Zegher F, Baxter R C, Veldhuis J D, Wouters P, Schetz M, et al. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 1998; 83: 309–19
   PubMed Web of Science ®Google Scholar
• Van Den Berghe G, Wouters P, Weekers F, Mohan S, Baxter R C, Veldhuis J D, et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999; 84: 1311–23
   PubMed Web of Science ®Google Scholar
• Bengtsson B A. Rethink about growth hormone therapy for critically ill patients (letter). Lancet 1999; 354: 1403–4
   PubMed Web of Science ®Google Scholar
• Bengtsson B A. Growth hormone replacement therapy is not associated with any increase in mortality (letter). J Clin Endocrinol Metab 1999; 84: 4291
   PubMed Web of Science ®Google Scholar
• Demling R. Growth hormone therapy in critically ill patients. N Engl J Med 1999; 341: 837–8
   PubMed Web of Science ®Google Scholar